APOH and autoimmune polyendocrinopathy: Given that microvascular thrombosis in mice can be neutralized by therapeutics targeting the interaction between β2GPI and anti-β2GPI antibodies [31,33], it is perhaps not surprising that plasmapheresis (i.e., removal of anti-β2GPI antibodies) remains the most time-tested approach for the treatment of severe microvascular APS in humans [62].